Breaking News Bar
updated: 5/31/2014 10:46 AM

New drugs may make a dent in lung, ovarian cancer

Success - Article sent! close
Associated Press

CHICAGO -- For the first time in a decade, an experimental drug has extended the life of patients with advanced lung cancer who relapsed after standard chemotherapy.

But the benefit in the study was so small -- six extra weeks, on average -- that it is raising fresh questions about the value of some costly new cancer medicines.

Eli Lilly and Co.'s drug Cyramza (sih-RAM-zuh) was tested in more than 1,200 patients. It is sold now for stomach cancer and costs $6,000 per infusion.

The study was discussed Saturday at a cancer conference in Chicago where doctors also reported progress with new drugs against relapsed ovarian cancer and chronic lymphocytic leukemia, the most common type of leukemia in adults.

Share this page
Comments ()
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked. If a comment violates these standards or our terms of service, click the X in the upper right corner of the comment box. To find our more, read our FAQ.